Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis in Alternative Donor Stem Cell Transplantation: Immune Reconstitution and Infection Risk

Allogeneic hematopoietic cell transplantation (HSCT) is a curative treatment modality for patients with various hematological malignancies and mainly high risk acute myeloid and lymphatic leukemia. For patients that are in need of transplant and lack human leukocyte antigen (HLA) matched sibling donors the most frequent alternatives are HSCT from HLA matched unrelated (MUD) and haploidentical donors [1,2]. The number of haploidentical stem cell transplantations (haploSCT) is constantly increasing both in the United States and in Europe.Graft versus host disease (GVHD) is a major cause of morbidity and mortality after HSCT and is still the main transplant related obstacle for successful HSCT.

Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Authors: Arnon Nagler Tags: The Bottom Line Source Type: research